lapatinib has been researched along with Peritoneal Neoplasms in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Awasthi, N; Hassan, MS; Li, J; Schwarz, MA; Schwarz, RE; von Holzen, U; Williams, F | 1 |
| Chaluvally-Raghavan, P; Geethadevi, A; George, J; Gopinadhan Nair, GK; Kadamberi, IP; Lu, Y; Mills, GB; Nair, A; Nair, B; Parashar, D; Pradeep, S; Rader, JS; Ram, PT; Ramchandran, R; Tsaih, SW; Uyar, DS | 1 |
| Kurzrock, R; Parker, BA; Schwab, R; Yan, M | 1 |
| Dakhilm, SR; Haluska, P; Hartmann, LC; Keeney, GL; Moore, DF; Oberg, AL; Peethambaram, PP; Rowland, KM; Weroha, SJ; Ziegler, KL | 1 |
| Armstrong, DK; Carolla, RL; Fischer, EG; Garcia, AA; Godwin, AK; Lankes, HA; Leslie, KK; Liepman, MK; Mannel, RS; Sill, MW; Spirtos, NM | 1 |
2 trial(s) available for lapatinib and Peritoneal Neoplasms
| Article | Year |
|---|---|
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lapatinib; Middle Aged; Neoplasm Proteins; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Quinazolines; Receptor, ErbB-2; Survival Rate; Topotecan | 2011 |
A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Disease-Free Survival; ErbB Receptors; Female; Humans; Ki-67 Antigen; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Polymorphism, Genetic; Quinazolines | 2012 |
3 other study(ies) available for lapatinib and Peritoneal Neoplasms
| Article | Year |
|---|---|
Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma.
Topics: Adenocarcinoma; Anilides; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Line, Tumor; Esophageal Neoplasms; Female; Humans; Lapatinib; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasm Proteins; Paclitaxel; Peritoneal Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-met; Quinolines; Random Allocation; Receptor, ErbB-2; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; ErbB Receptors; Female; Forkhead Box Protein M1; Gene Knockdown Techniques; Humans; Lapatinib; Mice; Ovarian Neoplasms; Peritoneal Neoplasms; Receptor, ErbB-2; Signal Transduction; Thiostrepton; Transfection | 2020 |
HER2 aberrations in cancer: implications for therapy.
Topics: Ado-Trastuzumab Emtansine; Adult; Afatinib; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Male; Maytansine; Molecular Targeted Therapy; Mutation; Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Up-Regulation; Uterine Cervical Neoplasms | 2014 |